Clin2
NCT06513962Possibly a fitRecruiting

Triptorelin to protect ovaries in young women with cancer

Hematopoietic and Lymphatic System NeoplasmMalignant Solid Neoplasm

Part of Cancer, Women’s health & pregnancy clinical trials.

This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
60 people
Ages
Up to 39 years
Study type
Interventional

Who can take part

  • You are under 40 years old and have started your period (more than 6 months ago).
  • You have been diagnosed with your first cancer (not breast cancer).
  • Your planned chemotherapy includes a strong drug called an alkylating agent (like cyclophosphamide, ifosfamide, or others).
  • You have not had radiation to your pelvis or high-dose radiation to your brain.
  • You are not pregnant, not breastfeeding, and agree to use birth control during the study.
  • You do not have a condition like Turner syndrome, Fragile X, or Down syndrome that affects fertility.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05999994Recruiting· Phase 2
Testing new drugs for children and young adults with cancer

This trial tests several experimental drugs for children and young adults with cancer. It aims to find safe and effective treatments by matching participants to one of several drug studies based on their cancer type and health.

Birmingham, Alabama
NCT05328258Recruiting· Phase 3
Triptorelin to help protect fertility during cancer chemotherapy

This Phase 3 study tests whether a hormone medicine called triptorelin (a GnRH “fertility-protecting” medicine) can better protect ovarian function while you receive chemotherapy. The goal is to help preserve fertility and reduce the risk of early ovarian failure from cancer treatment.

Gothenburg
NCT05309746Recruiting
Save ovarian tissue before cancer treatment

This trial studies freezing (cryopreserving) ovarian tissue before treatment that may permanently affect fertility and hormone production. You might consider it if you are planning surgery, chemotherapy, or radiation soon and want to preserve future options.

Chicago, Illinois
NCT06525155Recruiting· Phase 3
GnRH agonist for endometriosis cysts

This trial tests a drug called GnRH agonist to see if it helps people with endometriosis cysts. It might offer a new treatment option for those with this condition.

Jakarta
NCT05982093Recruiting· Phase 2
Elacestrant with or without triptorelin for premenopausal breast cancer

This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.

Badalona, Barcelona
NCT07776171Not yet recruiting· Phase 2
Studying a new drug combo for recurrent ovarian cancer after prior treatments

This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.

Guangzhou, Guangdong

Hear when a new Hematopoietic and Lymphatic System Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.